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enced a greater degree of pain and discomfort as mea-
sured by the EQ-5D (P = 0.018) and a lower perception
of their health status using the EQ-VAS (P = 0.039). 
Statistically signiﬁcant differences between both groups
were detected in all domains of the VFQ-25, except
general and colour vision, although differences were
thought to be clinically signiﬁcant only for the ocular pain
domain. The RQLQ scores were also all found to differ
signiﬁcantly between groups (P < 0.001). The total of
both the public health care and private out-of-pockets
costs of SAC in our study population ranged on average
between £64.61 for a pensioner to £142.29 for a person
with SAC in paid employment. CONCLUSIONS: SAC is
a costly, highly prevalent, chronic condition associated
with signiﬁcant reductions in both ocular and general
quality of life, as well as ongoing out-of-pocket expenses
and health care costs.
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OBJECTIVES: To estimate the number of quality
adjusted life years (QALYs) for chronic, treatment-
resistant heroin addicts in the Netherlands during the 
ﬁrst year of treatment with either oral methadone alone
or oral methadone in combination with co-prescribed
heroin. METHODS: Randomly assigned patients (N =
430) completed EuroQol-5D questionnaires at months 2,
6, 10, and 12 after they started therapy. Utility values
were derived by applying existing time trade-off based
regression weights to the data. It was assumed that the
observed EuroQol scores and related utilities reﬂected 
the health status between the actual measurement and the
previous one available. In case of missing endpoint assess-
ments, the last observation was carried forward. QALYs
were calculated as the mean health utility during follow-
up, weighted for the number of months preceding each
follow-up measurement. It was hypothesized that co-
prescription of heroin would lead to more QALYs.
RESULTS: About half of all treatment-resistant heroin
addicts suffered pain or discomfort and felt anxious or
depressed at baseline. In the ﬁrst year of treatment, a
patient on oral methadone alone generated 0.830 QALYs
on average (upper bound one-sided 95% conﬁdence
interval: 0.846), a patient on co-prescribed heroin 0.867
QALYs (lower bound one-sided 95% conﬁdence interval:
0.852). The numbers of QALYs generated per patient dif-
fered for the two groups (t = -2.72, p = 0.003 one-tailed).
Hence, the medical co-prescription of heroin resulted, on
average, in a 21.4% reduction of existing health loss.
CONCLUSIONS: Medical co-prescription of heroin in
addition to an oral methadone regimen is superior to an
oral methadone alone regimen. Further study will focus
on the cost-utility of co-prescribed heroin in this patient
population with special attention to the balance of
increasing health care costs and decreasing costs of illegal
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OBJECTIVES: Bulimia nervosa (BN) is characterised by
recurrent episodes of binge eating and secondly by com-
pensatory behaviour to prevent weight gain. Its preva-
lence has been estimated between 0.5% and 1.0% in
young women. A recent clinical guideline was commis-
sioned to establish the optimum clinical management of
BN in the UK. Antidepressants and bulimia nervosa spe-
ciﬁc cognitive behaviour therapy (CBT-BN) were identi-
ﬁed as the leading pharmacological and psychological
therapies in the clinical review. This study reports the
results of the cost-effectiveness analysis of these strategies
conducted as part of the guideline development process.
METHODS: A decision analytic model was developed to
calculate the incremental cost-effectiveness of antidepres-
sant therapy (ﬂuoxetine), CBT-BN and their combination
from the NHS’s viewpoint. Remission data were obtained
from the guideline meta-analyses, resource use data were
collected from the literature and experts. Unit costs were
calculated for year 2002/03. Different baseline scenarios
and uncertainty around the estimates (probabilistic analy-
sis) were explored. RESULTS: Combination therapy is
dominated by the other two strategies and was excluded
from the ﬁnal calculation. CBT-BN is more effective and
has higher treatment costs than ﬂuoxetine prescribed in
primary care with an incremental cost-effectiveness ratio
(ICER) of £4,807. The probability of CBT-BN being cost-
effective is 50% if decision makers are willing to pay
between £4,000–£5,000 for an additional successfully
treated BN case, but it increases to approximately 95%
if the threshold value is £10,000. CONCLUSIONS: Sig-
niﬁcant uncertainty around these results still exists (e.g.
the true cost of side effects of antidepressant therapy are
unknown, nor have attempts been made to quantify pos-
sible costs averted due to successful treatment). When
further research is carried out, it will be necessary to re-
estimate the cost-effectiveness of each alternative incor-
porating such inﬂuences. However, all these inﬂuences are
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likely to favour CBT-BN and so, current estimates may
be considered conservative.
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OBJECTIVES: HIT, hallucination focused integrative
therapy, aims at the integration of cognitive behaviour
therapy with, among others, psycho-education and single-
family treatment. The present study focused on the cost-
effectiveness of the HIT programme in patients with
schizophrenia and a history of persistent auditory hallu-
cinations. METHODS: Patients were randomly assigned
to two treatment arms, HIT or care as usual (CAU). The
economic evaluation was performed from a societal per-
spective, costs, and effects of both patient groups were
registered prospectively during a period of 18 months.
The PANSS (Positive and Negative Syndrome Scale) was
used as the primary outcome measure in the cost-effec-
tiveness analysis. Bootstrap analyses provided additional
information on the skewly distributed costs. RESULTS:
Mean costs of patients in the HIT-group ($18,237) were
lower than the mean costs of patients who received CAU
($21,436). The total amount of costs was inﬂuenced sub-
stantially by the costs of sheltered living accommoda-
tions, admissions in psychiatric hospitals and medication
use. Costs of medication (about 10% of total costs) were
relatively high in the present study, which is most likely
due to increasing use of expensive atypical antipsychotics
in recent years. Results of the PANSS were in favour of
the HIT-group. The economic analyses indicated that the
HIT-program was cost-effective in the current situation.
In addition, bootstrap analyses illustrated the probable
range of future variations in cost differences (-$12,050
to +$6,637) between both groups. CONCLUSIONS: The
HIT-program appeared to be cost-effective in the current
situation. Additional analyses indicated that future appli-
cation of this intervention will in most cases lead to a
reduction of societal costs.
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OBJECTIVE: To examine the cost of hospital care for
medical problems resulting from abuse of those aged 
>= 65 years old with Alzheimer’s disease, dementia or
another mental health disorder. METHODS: Four years
of hospital discharge data (1997–2000) from 5 states
were examined using ICD-9 diagnosis and E-codes to
identify reason for admission due to abuse, and the rela-
tionship to the abuser. These databases were used to
examine type of injury and to develop inpatient hospital
costs, length of stay (LOS), physician visit proﬁles and
disposition patterns. Medicare national fee schedules
were used for physician-related unit costs. Cost estimates
include accommodations, ancillary and physician services
and are reported in 2003 US$. Hospital charges were
adjusted by means of a 0.61 cost-to-charge ratio.
RESULTS: Of the 277 abuse cases identiﬁed, 78% were
female. The mean age was 79 years, 83% were admitted
via the Emergency Room and 96% resided in the com-
munity at time of admission. The abuser was coded as
spouse/partner, child, sibling, other relative, non-relative
in 37%, 28%, 2%, 18% and 15% of the cases, respec-
tively. The mean LOS was 6 days (median: 4, range:
1–49). The mean cost per stay was $7,875 (median:
$3,797, range: $766–$174,580). The hospital case fatal-
ity rate was 3%. Among survivors, 43% were discharged
home (11% with home health care), 47% required addi-
tional sub-acute inpatient care (i.e., rehabilitation, skilled
nursing, intermediate care), 9% were transferred to a
mental health or a residential care facility and 1% signed
out against medical advice. CONCLUSIONS: Abuse of
the elderly has economic, as well as clinical consequences.
Although substantial, hospital costs are but one aspect of
the cost picture, as these patients require injury-related
medical care beyond the hospital stay. This analysis draws
attention to the potential clinical and economic ramiﬁca-
tions arising from caregiver burden.
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OBJECTIVES: To provide information on ﬁnancial,
social and mental burden borne by the families of chil-
dren with ADHD. METHODS: A pilot-tested question-
naire was sent to all members of the Flemish ADHD
society. Data are collected on disease severity (IOWA-
CRS (Conners Rating Scale)), health care utilization, use
of social care and other non-medical resources; and on
socio-demographic and economic characteristics of the
parents. Data of the ADHD-children are compared with
data of their siblings, for which similar data are collected.
RESULTS: A total of 656 questionnaires were returned
(response rate 38.5%), however, the IOWA-CRS was
completed in only 379 questionnaires. The mean age of
the children with ADHD is 10.04 (range 3–16) and mean
